Efficacy of acupoint application in patients with overactive bladder: A randomized, placebo-controlled pilot trial

被引:0
作者
Tang, Heshu [1 ]
Zhu, Chunqin [2 ]
Xu, Suping [1 ]
Wang, Yan [1 ]
Gao, Juanjuan [1 ]
Zhou, Ping [1 ]
机构
[1] Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Dept Neurol, 155 Hanzhong Rd, Nanjing 210029, Peoples R China
[2] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Dept Nursing, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China
关键词
Overactive bladder; Acupoint application; Traditional Chinese medicine; OABSS; NGF; NERVE GROWTH-FACTOR; QUALITY-OF-LIFE; SYMPTOM; WOMEN;
D O I
10.1016/j.explore.2023.03.009
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective: Conventional treatments for alleviating the symptoms of Overactive bladder (OAB) have been reported to have limited efficacy and a high rate of side effects. Traditional Chinese medicine (TCM) has been used in Asia countries because of its low side effects and being easy to operate. To confirm the efficacy of acupoint application treatment for alleviating OAB symptoms, a randomized and placebo-controlled pilot trial was conducted in this study.Methods: All participants were randomly allocated into a treatment group or control group, receiving either a "Dinggui" acupoint application or placebo treatment for 4 weeks. The outcome measures were OAB symptom scores (OABSS), OAB questionnaire (OAB-q) scores, and TCM syndrome scores. Urine nerve growth factor (NGF) level, NGF normalized to urine creatinine (NGF/Cr), and maximum flow rate (Qmax) were also measured to evaluate the OAB symptoms. Results: In total, 69 participants were included with 34 in the treatment group and 35 in the placebo-treated group. Treatment with "Dinggui" acupoint application showed a statistically significant decrease in OABSS scores (8.10 & PLUSMN;1.54 to 3.67 & PLUSMN;1.77), OAB-q scores (61.43 & PLUSMN;13.93 to 38.13 & PLUSMN;15.42), and TCM syndrome scores (15.60 & PLUSMN;5.98 to 9.20 & PLUSMN;4.82). The NGF and NGF/Cr were also observed meaningful changes in a decrease from 379.68 to 136.17 pg/ml and from 0.30 to 0.16 pg/mg, respectively. The Qmax value showed a significant increase from 14.40 to 24.05 ml/s.Conclusions: Treatment with "Dinggui" acupoint application could be considered an effective and alternative therapy for OAB management. Further studies with larger sample sizes and longer treatment periods are needed to investigate.
引用
收藏
页码:749 / 754
页数:6
相关论文
共 50 条
  • [31] Flexible-Dose Fesoterodine in Elderly Adults with Overactive Bladder: Results of the Randomized, Double-Blind, Placebo-Controlled Study of Fesoterodine in an Aging Population Trial
    Wagg, Adrian
    Khullar, Vik
    Marschall-Kehrel, Daniela
    Michel, Martin C.
    Oelke, Matthias
    Darekar, Amanda
    Bitoun, Caty E.
    Weinstein, David
    Osterloh, Ian
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2013, 61 (02) : 185 - 193
  • [32] Efficacy and Safety of Solifenacin Succinate 10 mg Once Daily: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial in Patients With Overactive Bladder
    Chu, Franklin
    Smith, Neila
    Uchida, Takeshi
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2009, 70 (06): : 405 - 420
  • [33] EARLY AND CONSISTENT IMPROVEMENTS IN URINARY SYMPTOMS AND QUALITY OF LIFE WITH ONABOTULINUMTOXINA IN OVERACTIVE BLADDER PATIENTS WITH URINARY INCONTINENCE IN A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 4 TRIAL
    McCammon, Kurt
    Gousse, Angelo
    Gruenenfelder, Jennifer
    Hale, Douglass
    Orejudos, Amelia
    Aboushwareb, Tamer
    Patel, Anand
    Kohan, Alfred
    [J]. TOXICON, 2018, 156 : S79 - S79
  • [34] Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial
    Weber, Michael A.
    Haag-Molkenteller, Cornelia
    King, Jennifer
    Walker, Ann
    Mudd, Paul N., Jr.
    White, William B.
    [J]. BLOOD PRESSURE MONITORING, 2022, 27 (02) : 128 - 134
  • [35] Efficacy of the combination of transcutaneous tibial nerve stimulation and mirabegron in women with overactive bladder in a prospective randomized controlled trial
    Ya-Xiong Xu
    Yu Xiong
    Hong-qiang Tian
    Yan-hao Yang
    Rong-zhen Tao
    Yun-Peng Li
    [J]. Scientific Reports, 14 (1)
  • [36] Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
    Flynn, Michael K.
    Amundsen, Cindy L.
    Perevich, MaryAnn
    Liu, Fan
    Webstert, George D.
    [J]. JOURNAL OF UROLOGY, 2009, 181 (06) : 2608 - 2615
  • [37] Efficacy and Safety of Eliapixant in Overactive Bladder: The 12-Week, Randomised, Placebo-controlled Phase 2a OVADER Study
    Ewerton, Flavio
    Cruz, Francisco
    Kapp, Moritz
    Klein, Stefan
    Roehm, Petra
    Chapple, Christopher
    [J]. EUROPEAN UROLOGY FOCUS, 2024, 10 (01): : 90 - 97
  • [38] Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device
    Zhang, Yaoguang
    Zhang, Peng
    Tian, Xiaojun
    Chen, Guoqing
    Li, Yan
    Zhang, Yong
    Xu, Zhihui
    Wei, Zhongqing
    Zhang, Wei
    Ma, Lulin
    Shi, Benkang
    Liao, Limin
    Wang, Jianye
    [J]. WORLD JOURNAL OF UROLOGY, 2019, 37 (11) : 2481 - 2492
  • [39] Efficacy of overactive neurogenic bladder treatment : A systematic review of randomized controlled trials
    Bapir, Rawa
    Bhatti, Kamran Hassan
    Eliwa, Ahmed
    Garcia-Perdomo, Herney Andres
    Gherabi, Nazim
    Hennessey, Derek
    Magri, Vittorio
    Mourmouris, Panagiotis
    Ouattara, Adama
    Perletti, Gianpaolo
    Philipraj, Joseph
    Stamatiou, Konstantinos
    Trinchieri, Alberto
    Buchholz, Noor
    [J]. ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2022, 94 (04) : 492 - 506
  • [40] Acupuncture for overactive bladder in female adult: a randomized controlled trial
    Zhengyong Yuan
    Changxiao He
    Shibing Yan
    Donglai Huang
    Hanhui Wang
    Wei Tang
    [J]. World Journal of Urology, 2015, 33 : 1303 - 1308